MERT TOHUMCUOĞLU

Dr. MERT TOHUMCUOĞLU

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
CMCem Mirili
Cem Mirili
SPSemra Paydas
Semra Paydas
IGIsa Burak Guney
Isa Burak Guney
AOAli Ogul
Ali Ogul
SGSerkan Gokcay
Serkan Gokcay
GSGulsah Seydaoglu
Gulsah Seydaoglu
Purpose: The aim of this study was to evaluate the prognostic and predictive value of neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (DNLR), lymphocyte-to- monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) in soft tissue sarcoma (STS) cases treated with pazopanib. Materials and methods: The study population included 26 STS cases treated with pazopanib for at least 3 months. NLR, DNLR, LMR, and PLR were evaluated at baseline, and at third month of therapy and also compared with response to pazopanib. Median measurements were taken as cutoff for NLR (4.8), DNLR (3.1), LMR (3.6), and PLR (195). The associations between these cutoff values and survival times (progression-free survival [PFS] and overall survival [OS]) were assessed by Kaplan–Meier curves and Cox proportional models. Results: Patients with low pretreatment NLR and DNLR had longer OS (P=0.022, P=0.018), but low PLR was found to be associated only with longer OS. Additionally, decrease in NLR and DNLR after 3 months of therapy as compared with pretreatment measurements was found to be associated with an advantage for OS (P=0.021, P=0.010, respectively) and PFS (P=0.005, P=0.001, respectively). Response to pazopanib; changes in NLR, DNLR, LMR, and PLR; and >3 metastatic sites were found to be independent risk factors in univariate analysis, but NLR was the only independent risk factor in multivariate analysis. Conclusion: Low pretreatment and decrease in NLR and DNLR values, and regression/stable disease after 3 months of pazopanib are predictive factors for longer OS and PFS.

1 January 2024 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
MBMahmut Buyuksimsek
Mahmut Buyuksimsek
AGahmet gulmez
ahmet gulmez
OPOkan Pirinci
Okan Pirinci
MTMERT TOHUMCUOĞLU
MERT TOHUMCUOĞLU
MKMehmet Mutlu KIDI
Mehmet Mutlu KIDI
The aim of this study was to evaluate depression and sleep quality in Turkish women receiving neoadjuvant or adjuvant chemotherapy for breast cancer and investigate their relationship.

19 November 2020 in Turkish Journal of Hematology
Verified
Journal Article
Open access
MBMahmut Buyuksimsek
Mahmut Buyuksimsek
IKİrem Kolsuz
İrem Kolsuz
AYAbdullah Evren Yetişir
Abdullah Evren Yetişir
MTMERT TOHUMCUOĞLU
MERT TOHUMCUOĞLU
AOAli Ogul
Ali Ogul
IGIsa Burak Guney
Isa Burak Guney
Objective: Bone marrow infiltration (BMI) affects the stage diagnosis, and treatment of lymphoma. We aimed to evaluate the performance of bone marrow biopsy (BMB) and positron emission tomography-computed tomography (PET/CT) in detecting BMI in lymphoma patients. Materials and Methods: A total of 269 non-Hodgkin's lymphoma (NHL) and 110 Hodgkin's lymphoma (HL) patients were evaluated retrospectively. Sensitivity, negative predictive value (NPV), and accuracy were calculated for PET/CT and BMB in detecting BMI. Results: Sensitivity, NPV, and accuracy for PET/CT in detecting BMI in NHL cases were 65%, 78%, and 84.4%, respectively, while they were 55%, 73.4%, and 79.9% for BMB. PET/CT performance for diffuse large B-cell lymphoma and follicular lymphoma was better than that of BMB, whereas the performance of BMB was better for mantle-cell lymphoma, Burkitt's lymphoma, and primary mediastinal B-cell lymphoma. Sensitivity, NPV, and accuracy for PET/CT in HL cases were 91.3%, 97.75%, and 98.18%, respectively, while they were 56.52%, 89.69%, and 90.91% for BMB. Due to BMB, 43 (15.9%) patients in the NHL group and 2 (1.8%) patients in the HL group were protected from downstaging. Conclusion: Although their results vary according to NHL subtypes, PET/CT and BMB are complementary methods in determining BMI. In HL, PET/CT is an important diagnostic tool for detecting BMI, and BMB is not necessary in a significant proportion of cases.

22 December 2025 in Cukurova Medical Journal
Verified
Journal Article
Open access
MTMERT TOHUMCUOĞLU
MERT TOHUMCUOĞLU
MBMahmut Buyuksimsek
Mahmut Buyuksimsek
Purpose: The aim of this study was to evaluate overall and progression-free survival and explore subgroup differences in a single-center retrospective cohort of patients with advanced soft-tissue sarcoma receiving pazopanib. Materials and Methods: A single-center retrospective cohort study included 45 adults with locally advanced or metastatic non-adipocytic soft-tissue sarcoma who initiated pazopanib between March 2020 and December 2024. Data were extracted from institutional electronic records (pathology, imaging, treatment, and follow-up). Overall survival (OS; from pazopanib initiation to death) and progression-free survival (PFS; from initiation to disease progression or death) were estimated using the Kaplan–Meier method with 95% confidence intervals. Results: Forty-five patients were analyzed. Median PFS was 4.50 months (95% CI, 2.28–10.26) and median OS was 6.90 months (95% CI, 2.85–17.36); 1-year OS was 35.6%. Event rates were 82.2% for progression and 73.3% for death during follow-up. No subgroup differences reached significance for either PFS or OS; in Kaplan–Meier/log-rank comparisons, OS was numerically longer in patients with prior radiotherapy (16.53 vs 6.90 months). Conclusion: These real-world data suggest that pazopanib maintains disease control consistent with the efficacy reported in the phase III randomized trial, whereas baseline risk profile and subsequent therapies are likely to influence overall survival; these findings should be confirmed in larger prospective multicenter cohorts.

31 December 2025 in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
Verified
Journal Article
Closed access
MTMERT TOHUMCUOĞLU
MERT TOHUMCUOĞLU
MKMehmet Mutlu KIDI
Mehmet Mutlu KIDI
MBMahmut Buyuksimsek
Mahmut Buyuksimsek
Purpose: To describe real-world outcomes of trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and to explore clinical factors associated with survival. Methods: This retrospective single-center cohort included women with HER2-positive metastatic breast cancer who received at least one cycle of T-DM1 between March 2020 and January 2025 at Adana City Training and Research Hospital. Demographic, clinicopathologic and treatment-related data were collected from electronic health records. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and prespecified subgroups were compared using two-sided log-rank tests. Results: Sixty-one patients were included; median age at T-DM1 initiation was 52 years (range, 34–82). All had received prior trastuzumab-based therapy, most had been treated with taxanes and pertuzumab, and T-DM1 was used predominantly as second-line treatment. Median PFS was 8.1 months (95% CI, 6.9–9.2) and median OS was 24.5 months (95% CI, 22.7–26.3). The objective response rate was 55.7%, with stable disease in 8.2%. ECOG performance status was the strongest prognostic factor. Patients with ECOG 0–1 had longer PFS (10.9 vs 5.9 months) and OS (30.3 vs 10.5 months) than those with ECOG 2. Median OS was shorter in patients with brain/CNS metastases than in those without (8.9 vs 25.1 months), while PFS did not differ meaningfully between these groups. Conclusion: In this real-world cohort, T-DM1 provided PFS, OS and response rates comparable to those reported in clinical trials, in a population previously treated with trastuzumab- and pertuzumab-based first-line therapy and receiving T-DM1 predominantly as second-line treatment. Performance status and brain/CNS involvement were key determinants of outcome. These findings emphasize the prognostic role of performance status and the continuing need for more effective approaches in patients with brain/CNS metastases.

13 June 2020 in Anadolu Kliniği Tıp Bilimleri Dergisi
Verified
Journal Article
Open access
PDF file
MBMahmut Buyuksimsek
Mahmut Buyuksimsek
SPSemra Paydas
Semra Paydas
SBServet Başdoğan
Servet Başdoğan
MTMustafa Toğun
Mustafa Toğun
AYAbdullah Evren Yetişir
Abdullah Evren Yetişir
MTMERT TOHUMCUOĞLU
MERT TOHUMCUOĞLU
Amaç: Meme kanseri kadınlarda en sık görülen ve en sık ölüme neden olan kanserdir. Biz de merkezimizde takip ettiğimiz metastatik meme kanseri (MMK) olan hastaların klinik özelliklerini ve tedavi sonuçlarını araştırmak istedik. Gereç ve Yöntemler: Çukurova Üniversitesi Onkoloji bilim dalında 2011-2017 yılları arasında takip edilen 65 MMK olan hasta çalışmaya dahil edildi. Hastaların klinik özellikleri ve aldıkları tedaviler retrospektif olarak araştırıldı. Bulgular: Hastaların büyük çoğunluğunda sadece kemik metastazı vardı. Sonradan metastatik evreye geçen 45 hastanın %66,6’ sına yeniden biyopsi yapıldı; bu hastaların %20’ sinde tümör biyolojisi değişmişti. Metastatik evrede progresyonsuz sağkalım 10 ay, ortalama sağkalım 34 ay olarak hesaplandı. Tartışma ve Sonuç: MMK olan hastalarda literatürle uyumlu sağkalımlar elde edilmiştir. Yeni kullanıma giren ajanlar ve hedefleyici tedavilerdeki gelişmeler de göz önüne alındığında hastalık biyolojisindeki değişme ihtimali göz önünde bulundurularak relapslarda yeniden biyopsi yapılması kritik önemdedir.